[Treatment with praziquantel of schistosomiasis carriers in an endemic area, with persistent positivity after successive administration of oxamniquine].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002353:Carrier State / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005243:Feces / Q000469:parasitology; D006801:Humans; D007223:Infant; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D007546:Isoquinolines / Q000627:therapeutic use*; D008875:Middle Aged; D010073:Oxamniquine / Q000627:therapeutic use; D011223:Praziquantel / Q000627:therapeutic use*; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*
D007546:Isoquinolines; D010073:Oxamniquine; D011223:Praziquantel
Tratamento com praziquantel de portadores de esquistossomose, em área endêmica, com persistência de positividade após sucessivas administrações de oxamniquine.